Convalescent plasma reduces hospitalization risk in COVID-19

Convalescent plasma, when administered within 9 days of symptom onset in patients with COVID-19, may reduce the risk for hospitalization, according to data published in The New England Journal of Medicine.
“While everyone was focused on treating people in the hospital after progression of disease, we saw the need to keep people out of the hospital rather than wait until they were near death,” David J. Sullivan, MD, of the Johns Hopkins Bloomberg School of Public Health, in Baltimore, told Healio. “We planned the highest level of evidence a randomized control trial to

Convalescent plasma, when administered within 9 days of symptom onset in patients with COVID-19, may reduce the risk for hospitalization, according to data published in The New England Journal of Medicine.
“While everyone was focused on treating people in the hospital after progression of disease, we saw the need to keep people out of the hospital rather than wait until they were near death,” David J. Sullivan, MD, of the Johns Hopkins Bloomberg School of Public Health, in Baltimore, told Healio. “We planned the highest level of evidence a randomized control trial to